(Epi)transcriptomics in cardiovascular and neurological complications of COVID-19

Amela Jusica,b, Konstantinos Stellos c,d,e,f, Lino Ferreirag,h, Andrew H. Bakeri,j, Yvan Devaux a,*

* Cardiovascular Research Unit, Department of Precision Health, Luxembourg Institute of Health, 1A-B rue Edison, 1445 Strassen, Luxembourg
b Department of Biology, Faculty of Natural Sciences and Mathematics, University of Tuzla, 75000 Tuzla, Bosnia and Herzegovina
c Department of Cardiovascular Research, European Centre for Angioscience (ECAS), Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
d German Centre for Cardiovascular Research (Deutsches Zentrum für Herz-Kreislauf-Forschung, DZHK), Heidelberg/Mannheim Partner Site, Mannheim, Germany
e Department of Cardiology, University Hospital Mannheim, Mannheim, Germany
f Centre for Cardiovascular Science, University of Edinburgh, Queen's Medical Research Institute, 47 Little France Crescent, Edinburgh EH16 4TJ, UK
g CNC-Center for Neurosciences and Cell Biology, CIBB-Centre for Innovative Biomedicine and Biotechnology, University of Coimbra, Portugal
h Faculty of Medicine, University Coimbra, 3000-548 Coimbra, Portugal
i CARIM Institute, University of Maastricht, Universiteitszangt 50, 6200 MD Maastricht, the Netherlands
j Department of Cardiology, University Hospital Mannheim, Mannheim, Germany

ARTICLE INFO

Keywords: Brain-heart axis COVID-19 RNAs

ABSTRACT

Although systemic inflammation and pulmonary complications increase the mortality rate in COVID-19, a broad spectrum of cardiovascular and neurological complications can also contribute to significant morbidity and mortality. The molecular mechanisms underlying cardiovascular and neurological complications during and after SARS-CoV-2 infection are incompletely understood. Recently reported perturbations of the epitranscriptome of COVID-19 patients indicate that mechanisms including those derived from RNA modifications and non-coding RNAs may play a contributing role in the pathogenesis of COVID-19.

In this review paper, we gathered recently published studies investigating (epi)transcriptomic fluctuations upon SARS-CoV-2 infection, focusing on the brain-heart axis since neurological and cardiovascular events and their sequelae are of utmost prevalence and importance in this disease.

Contents

1. Introduction .................................................................................................................. 1
   2. Epitranscriptomic signature in the brain-heart axis of COVID-19 patients .................... 2
      2.1. Noncoding RNAs in the brain-heart axis .......................................................... 2
      2.2. Small noncoding RNAs .................................................................................. 3
      2.3. Long noncoding RNAs ................................................................................... 3
      2.4. Epitranscriptomics ........................................................................................... 4
      2.5. RNA editing of the viral RNA ......................................................................... 4
   3. Crosstalk between RNAs and endo/extracellular inflammation and vascular dysfunction in COVID-19 .......................................................... 5
      3.1. Brain-heart crosstalk ....................................................................................... 5
      3.2. Diagnostic potential of nRNA in COVID-19 .................................................... 6
      3.3. Future of COVID-19 diagnostics and therapy .................................................. 6
      3.4. Extracellular vesicles based COVID-19 therapeutics ....................................... 6
   4. Concluding remarks and future perspectives ............................................................. 6
   5. Funding ..................................................................................................................... 7
   6. Author contributions ............................................................................................... 7
   7. Declaration of competing interest .......................................................................... 7
   8. Acknowledgements ................................................................................................. 7
   9. References .............................................................................................................. 7
   10. Glossary ................................................................................................................. 7

* Corresponding author at: Cardiovascular Research Unit, Luxembourg Institute of Health, 1A-B rue Edison, 1445 Strassen, Luxembourg.
E-mail address: yvan.devaux@ilh.lu (Y. Devaux).

http://dx.doi.org/10.1016/j.jmccpl.2022.100013
Received 9 June 2022; Received in revised form 14 July 2022; Accepted 15 July 2022
2772-9761/© 2022 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction

Coronavirus disease (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) demonstrating a wide spectrum of clinical manifestations, from asymptomatic, mild flu-like illness to lethal acute respiratory distress syndrome. The SARS-CoV-2 enters human cells by binding to angiotensin-converting enzyme type 2 (ACE2), a transmembrane receptor expressed by pulmonary and inflammatory cells, but also by other cell types including cardiomyocytes, pericytes and neurons (Fig. 1). Functionally, ACE2 inactivates angiotensin II [1] and plays an important role in neuro-humoral regulation of the cardiovascular system. In severe cases, SARS-CoV-2 invasion of the host cells may result in progression toward the “COVID-19 cytokine storm” which is characterized by severe immune reaction and overwhelming systemic inflammation, haemodynamic instability and multiple organ failure with known and unknown clinical complications [2,3]. Although, SARS-CoV-2 primarily affects the lungs, reports are emerging of the wide spectrum of cardiovascular and neurological manifestations and complications ranging from the de novo viral infection or its interplay with pre-existing comorbidities (Fig. 1). The underlying cardiovascular and neurological comorbidities seem to predispose the development of more severe cardiovascular and neurological complications in COVID-19 patients, which are in turn associated with higher mortality rates [4]. History of cardiovascular disease is associated with a nearly five-fold increased risk in fatality rates [5]. Most prevalent cardiovascular disease risk factors in COVID-19 patients are hypertension and diabetes mellitus, while most common cardiovascular complications observed in COVID-19 patients include arrhythmias, acute myocardial infarction, cardiac injury, fulminant myocarditis, pericarditis, cardiac arrhythmia, heart failure, and disseminated intravascular coagulation [6,7]. The interaction between underlying cardiovascular comorbidities and the poor clinical outcome of COVID-19 may be multifaceted, including age, sex, cardiac dysfunction [8] and aorta ageing as defined by the estimated pulse wave velocity [9].

Neurological and psychiatric sequelae of COVID-19 have been widely reported (Fig. 1) [10,11]. A retrospective study among 236,379 patients diagnosed with COVID-19 estimated that the incidence of a neurological or psychiatric diagnosis in the following six months after infection was 33.62 % [12]. SARS-CoV-2 was recently detected in vivo in transgenic mice overexpressing human ACE2 and in post mortem cortical neurons of COVID-19 patients, showing the neuroinvasive capacity of SARS-CoV-2 [13]. However, the potential molecular mechanisms underlying cardiovascular and neurological complications during and post SARS-CoV-2 infection have not been fully elucidated.

Possible mechanisms include direct virus-mediated neurocardiotoxicity, hypoxia-related injury, immune-mediated cytokine storm and systemic inflammation, and so forth. Recently reported perturbations of the epitranscriptome of COVID-19 patients indicate that mechanisms including those derived from RNA modifications and non-coding RNAs may play a contributing role in both short- and long-term cardiovascular and neurological outcomes.

2. Epitranscriptomic signature in the brain-heart axis of COVID-19 patients

2.1. Noncoding RNAs in the brain-heart axis

Eukaryotic cells produce different classes of non-protein coding RNA transcripts called ncRNAs participating in various cellular processes including, gene expression regulation, RNA maturation and protein synthesis. NcRNAs are transcribed by either RNA polymerase I, II or III, depending

---

Fig. 1. Interplay between SARS-CoV-2 infection, neurological and cardiovascular complications. 1) Underlying neurological and cardiovascular comorbidities are associated with high mortality in patients with COVID-19. 2) Multiple molecules at the cell surface are involved in the entry of SARS-CoV-2, including the major receptor ACE2, the membrane protease TMPRSS2, and other potential alternative/auxiliary receptors or cofactors such as cathepsin L, a transmembrane glycoprotein CD147, high-density lipoprotein (HDL) scavenger receptor B type 1 (SR-B1) and neuropilin-1. The initial step of SARS-CoV-2 infection involves specific binding of spike protein (S) to the cellular entry receptor ACE2 and priming of S protein by TMPRSS2 at the cell surface or by cathepsin L in the endosomal compartment following ACE2-mediated endocytosis. After activation of the S2 domain on the spike, the virus enters the cell via membrane fusion. 3) Although the main presentation of COVID-19 is viral pneumonia, SARS-CoV-2 infection can also induce neurological and cardiovascular complications. Since the expression and tissue distribution of ACE2 dictates viral tropism and pathogenicity, ACE2 may facilitate direct invasion of neurons or myocardial cells leading to apoptosis and necrosis of neurons/cardiac and neighbouring cells. On the other hand, cytokine storm can damage an intact blood–brain barrier and disrupt the homeostasis of the central nervous system without the virus crossing the blood–brain barrier from the systemic circulation. In the cardiovascular system, an acute coronary syndrome can occur because of plaque rupture, coronary spasm or micro-thrombi owing to systemic inflammation or cytokine storm. In addition, the SARS-CoV-2 infection is associated with a pro-thrombotic state, which may lead to occlusion of blood vessels leading to injuries of both the heart and the brain. A part of this figure was created using “Mechanism of “SARS-CoV-2 Viral Entry” and “Cytokine storm” templates by BioRender.com (2020). Retrieved from https://app.biorender.com/biorender-templates.
on the individual ncRNA [14]. According to their lengths, they can be divided into two main groups: (1) small or short ncRNAs including microRNAs (miRNAs), small interfering RNAs (siRNAs), PIWI-interacting RNA (piRNA) and small nucleolar RNAs ( snoRNAs); and (2) long noncoding RNAs (lncRNAs) and circular RNAs (circRNAs) [15]. A rapidly growing number of studies has unravelled associations between aberrant ncRNA expression and human diseases. NcRNAs have emerged as promising candidates for the treatment of a variety of diseases and play a potential significant role in host-virus interactions [15]. Dysregulated noncoding RNAs (ncRNAs) expression levels in lung tissue and liquid biopsies from COVID-19 patients indicate that ncRNAs may play an important role in the pathogenesis, and hence clinical outcomes of COVID-19. For instance, altered levels of ncRNAs involved in T cell activation and differentiation have been found in peripheral blood mononuclear cell samples from COVID-19 patients at three different time points during their treatment, convalescence, and rehabilitation [16].

2.2. Small noncoding RNAs

Due to limited cardiac and brain tissues availability for research purposes, SARS-CoV-2-mediated neuro-cardiovascular transcriptome changes were investigated in liquid biopsies (plasma, serum and whole blood), human induced pluripotent stem cells (iPSC)-derived cardiomycocytes, human brain endothelial cells and human cholinergic neurons. Small ncRNAs (particularly miRNAs) associated with cardiovascular and neurological complications in COVID-19 patients are summarized in Table 1.

In human brain microvascular endothelial cells (hBMECs), miR-24 targets cell surface receptor neuropilin-1 (NRP1), indicating its potential role in the neurological manifestation of COVID-19 [17]. Upregulation of miR-24 significantly reduced the permeability of hBMECs resulting in response of VEGF, an agonist of Neuropilin-1, which lead to the Neuropilin-1 overexpression of hypothalamic cells potentially playing a role in the regulation of hypothalamic circuits known to be exposed to the entry of the virus via the olfactory bulb, the regulation of its interaction with SARS-CoV-2 is not yet fully understood.

Oxidative stress-induced miR-200c targets SARS-CoV-2 entry receptor ACE2 in rat primary cardiomycocytes and human iPSC-derived cardiomycocytes [20]. Two cardiometabolic miRNAs, miR-133a and miR-122 were associated with 28-day mortality of COVID-19 patients [21]. Serum levels of inflammation (miR-155) and cardiac myocyte-enriched miRNAs (miR-21, miR-208a and miR-499) were increased in COVID-19 patients compared to healthy controls, indicating an association between SARS-CoV-2 infection and cardiovascular issues [19]. A comprehensive analysis of transcriptional expression profiles obtained from whole blood of moderate and severe COVID-19 patients has revealed several miRNAs such as miR-146a-5p, miR-21-5p, and miR-142-3p that may serve as potential biomarkers of disease severity [18]. The same study has highlighted three miRNAs, miR-146a-5p, miR-21-5p, and miR-142-3p, as potential therapeutic targets of COVID-19 [18].

2.3. Long noncoding RNAs

An increasing number of IncRNAs with potential neurological and immunological functions has been shown to be associated with the pathogenesis of COVID-19 (Table 2). Deep RNA sequencing of SARS-CoV-2-infected lung tissues and human-derived differentiated cholinergic neurons revealed several differentially expressed IncRNAs, reflecting their association with the inflammatory pathobiology related to COVID-19. For instance, transcriptomic analyses in lung has shown that two IncRNAs, DANCRI and NEAT1, may predict the inflammatory profile of infected tissues and provide insights into adverse body and brain consequences of COVID-19 [31]. The IncRNA DANCRI regulates inflammation and is responsible for the surveillance over cholinergic blockade of inflammation, thereby maintaining a balance between pro- and anti-inflammatory pathways in lung and brain tissues affected by SARS-CoV-2 [31]. In another study, expression levels of three IncRNAs, MALATI, NEATI, and SNGH255 were found to be downregulated in mild and severe COVID-19 patients [33]. Interestingly, MALATI and NEATI are implicated in both, cardiovascular and neurological complications. Recent findings on differential ncRNA expressions across SARS-

| Table 1 | aberrantly expressed miRNAs associated with the brain-heart axis and inflammation after SARS-CoV-2 infection. |
|--------|----------------------------------------------------------------------------------------------------------|
| miRNA  | Type of sample | Regulation | Validated targets in COVID-19 | Reference |
| Brain  | miR-24 | hBMECs | ↑ | NRP1 | [17] |
| Cardiac | miR-21-5p | Serum, RBC-depleted whole blood, | ↑ | MYC | [18,19] |
|        | miR-200c | NRComs, NRCEs, HCFs, HUVECS, cord blood derived hiPSC-CMs | ↓ | ACE | [20] |
|        | miR-133a, miR-122 | Plasma | ↓ | – | [21] |
|        | miR-208a | Serum | ↑ | – | [19] |
|        | miR-499 | ↑ | FoxO1 | |
| Inflammation | miR-155 | ↑ | – | [22,23] |
|        | miR-16-2-3p | Blood | ↑ | – | |
|        | miR-6501-5p | ↑ | – | |
|        | miR-618 | ↑ | TLR-4, HATI, TGF-β2 | |
|        | miR-183-5p | ↓ | Pten | |
|        | miR-627-5p | ↓ | – | |
|        | miR-144-3p | ↓ | FoxO1 | |
|        | miR-423-5p | Plasma | ↓ | – | [24] |
|        | miR-23a-3p | ↓ | – | |
|        | miR-195-5p | ↑ | – | |
|        | miR-1207-5p | Lung tissue | ↑ | CSF1 | [25] |
|        | miR-146a-5p | Serum, RBC-depleted whole blood, | ↓ | IL-6, STAT1 | [18,26] |
|        | miR-429 | RBC-depleted whole blood | ↓ | – | [18] |
|        | miR-142-3p | ↑ | IL6ST | |
|        | miR-15b-5p | ↑ | IFNG, CD69 | |
|        | miR-26a-5p | Post mortem lung tissue | ↓ | – | [27] |
|        | miR-29b-5p | ↑ | – | |
|        | miR-34a-5p | ↑ | – | |

hBMECs indicates human brain microvascular endothelial cells, HCFs – human cardiac fibroblasts, hiPSC-CMs - human induced pluripotent stem cell-derived cardiomycocytes, HUVECs – human umbilical vein endothelial cells, NRComs - neonatal rat cardiac myocytes, NRCEs - neonatal rat cardiomyocytes, RBC – red blood cells.
Table 2

| IncRNA | Type of sample | Regulation | Pathways related to COVID-19 | Reference |
|--------|----------------|------------|------------------------------|-----------|
| NcnRNA| Lung tissue, brain, PBMCs | ↑ | mTOR, RUNX3, SPI1 | [31] |
| NEAT1 | Lung tissue, brain, PBMCs, HUVECs | ↓ | - | [31-34] |
| MALAT1 | PBMCs | → | - | [32,33] |
| SNGH25 | PBMCs | ↓ | - | [32] |
| AC012065.4 | PBMCs | ↑ | - | [35] |
| AL365203.2 | PBMCs | ↓ | - | [36] |
| AC010175.1 | AC010904.2 | ↑ | IL-7 | [36] |
| LINC00562 | AL365203.2 | ↓ | - | [36] |
| AC010536.1 | AP005671.1 | ↑ | - | [36] |
| SNGH1 | PBMCs | ↑ | IL-7 | [36] |

Up and down arrows, indicate an increase and decrease of expression with increasing disease severity, respectively. PBMCs = peripheral blood mononuclear cells.

CoV-2 infected tissues and bio-fluids of COVID-19 patients indicate that ncRNAs may constitute key players in the regulation of the immune response following infection [28,29]. However, changes in ncRNAs landscape associated with cardiac and neurological manifestations of COVID-19 patients are yet to be fully characterized and their potential role in the course of the disease remains to be elucidated.

2.4. Epitranscriptomics

RNA modifications, collectively termed the ‘epitranscriptome’, can effectively affect every aspect of RNA metabolism, including splicing, non-coding RNA biogenesis and maturation, as well as RNA stability and non-sense mediated decay, comprising thus an additional level of gene regulation [37]. Among over 100 epitranscriptomics modifications, A-to-I RNA editing and N6-methyladenosine (m6A) are the most studied and abundant modifications that control multiple biological functions in the cell, including in the cardiovascular system [38]. In addition, numerous less charted and abundant RNA modifications have been identified, including N1-methyladenosine (m1A), N5-methylcytosine (m5C), N7-methylguanosine (m7G), N6,2′-O-dimethyladenosine (m6Am), and pseudouridine (Ψ) [39]. In recent years, RNA modifications have been identified on coding RNA (messenger RNA, mRNA) as well as on non-coding RNA species including miRNAs, ribosomosomes (rRNAs) and transfer RNA (tRNAs), snoRNAs, lncRNAs and circRNAs [40-43]. At the cellular level, dynamics of RNA modifications are finely regulated by different components of methylation machinery consisting of enzymes and proteins termed as writers, readers and erasers [44,45].

Adenosine-to-inosine (A-to-I) RNA editing, mediated by the adenosine deaminase RNA specific (ADAR) family of enzymes, is the most widespread RNA modification, taking place mainly in the primate-specific, repetitive Alu elements [46,47]. A recent study showed that ADAR1, the main RNA editing enzyme, was among the most upregulated genes in pulmonary alveolar type II cells of patients infected with SARS-CoV-2 [48], the main lung cells expressing the ACE2 receptor [49]. Similarly, ADAR1 expression was increased in peripheral blood cells of patients with severe COVID-19 compared to those with mild disease [50]. Increased ADAR1-induced RNA editing may affect the brain-heart axis in several ways. For instance, ADAR1 may prevent the excessive activation of innate immune receptors by the viral RNA [51], thus preventing the hyperinflammatory response and translational shutdown/apoptosis. Further, ADAR1 may prevent oxidative stress-induced inflammation and apoptosis in cardiomyocytes by inhibiting protein kinase R (PKR) hyperactivation [52]. Of interest, ADAR1 overexpression, which was also induced by oxidative stress, could limit PKR phosphorylation in cardiomyocytes [53], thus preventing the aberrant activation of innate immune sensors by viral double stranded RNA.

On the other hand, extensive RNA editing of the serotonin 5-hydroxytryptamine receptor 2C (5-HT2C-R) in the brain has been associated with aberrant sympathetic nervous activity [54]. 5-HT2C-R has five editing sites in exon 5 leading to 3 amino acid substitutions, which can alter the coupling with downstream G proteins by 10–15-fold [55]. Of note, a persistent hypermetabolic state is observed in patients with COVID-19 [56], especially in those admitted to intensive care units [57] contributing to patient deterioration. Similar, yet unknown, possible editing events in other serotonin receptors leading to an aberrant activation of the sympathetic nervous system could potentially lead to arrhythmias or even sudden cardiac death especially in individuals with underlying heart conditions [58].

2.5. RNA editing of the viral RNA

Apart from its effects on host gene expression and cellular function under stress conditions including apoptosis, RNA editing may control SARS-CoV-2 propagation per se (reviewed in [59]). RNA editing has two major forms, deamination of adenosine-to-inosine (A-to-I) and deamination of cytosine-to-uracil (C-to-U), mediated by the ADAR and APOBEC family of enzymes, respectively [47,60]. SARS-CoV-2 has a positive sense, single-stranded RNA genome of approximately 30-kilo bases length [61]. The high prevalence of C-to-U and A-to-G transitions [62], in sequence motifs compatible with ADAR/APOBEC-mediated deamination events observed in the human transcriptome [47,60,63], has suggested the involvement of host RNA editing machinery in SARS-CoV-2 mutagenesis. Editing of viral RNA can have either pro-viral or anti-viral effects depending on the host-virus interactions [64]; on one hand, editing events can affect viral protein synthesis by creating early stop codons (non-sense mutations). The complete lack of such A-to-G/C-to-U non-sense mutations in isolated genomic SARS-CoV-2 RNA from patient’s broncho-alveolar lavage samples [63] suggests that such events may be incompatible with viral replication. On the other hand, a single point mutation, such as the D614G (A-to-G) substitution in the spike (S), can greatly affect viral transmissibility by: i) affecting loading of the spike protein into virions, ii) changing its conformation into a more ACE2-binding-competent state or iii) increasing binding affinity to ACE2 [65,66]. Apart from the effects of site-specific editing events on viral propagation, extensive editing of the viral genome can affect its recognition by the host immune response. Heavily edited viral RNA can avoid recognition by innate immune receptors such as MDA-5 and PKR [64], thus avoiding the protective host immune response; on the other hand, hyper-editing of viral RNA can restrict viral replication or ‘mark’ viral RNA for degradation by endonucleases [67,68]. Thus, RNA editing on the SARS-COV-2 genome could be a relevant mechanism controlling the dynamics of viral evolution, affecting virulence, pathogenicity and host response [69].

3. Crosstalk between RNAs and endothelial inflammation and vascular dysfunction in COVID-19

Endothelial inflammation is a central component of COVID-19 pathogenesis [70]. COVID-19 can lead to endothelial inflammation and dysfunction by two main mechanisms: 1) direct infection of endothelial cells by SARS-CoV-2 and 2) endothelial activation by the systemic inflammatory response. While an early analysis of organ autopsies using electron microscopy showed endothelial cells from multiple organs were infected with SARS-CoV-2 [71], a more recent study showed low capability of direct endothelial infection by SARS-CoV-2, mainly attributed to the very low expression levels of ACE2 [72]. Whether SARS-CoV-2 can enter endothelial cells via secondary receptors when at high titres [72], or the observed vascular inflammation in COVID-19 can be mainly attributed to the infection of neighbouring vascular cells, e.g. pericytes, and to the systemic inflammatory response remains to be elucidated.

SARS-CoV-2 shows a unique immunological profile compared to other viral infections such as Influenza (flu) [50]. In contrast to other viruses, which lead to the upregulation of the anti-viral part of the innate immune response (type I interferons), SARS-CoV-2 infection is characterized by...
the up-regulation of proinflammatory cytokines, predominantly IL-6 [50]. IL-6 activates the endothelium and upregulates the expression of adhesion molecules [E-selectin, vascular cell adhesion molecule 1 (VCAM-1), intercellular adhesion molecule 1 (ICAM-1)] as well as chemokines [interleukin-8, monocyte chemoattractant protein-1 (MCP-1)] which control the recruitment of immune cells into inflamed tissues [73]. Of note, circulating levels of endothelial adhesion molecules, including ICAM-1, VCAM-1, and vascular adhesion protein 1 (VAP-1), have been associated with more severe disease or increased mortality in patients with COVID-19 [74,75]. Moreover, IL-6 trans-signalling can also increase plasminogen activator inhibitor-1 (PAI-1) production by endothelial cells [76], which may contribute to the thrombo-inflammatory cascade observed in COVID-19 patients [77].

Apart from the transcriptional alterations induced by systemic inflammation in endothelial cells, a systematic upregulation of ADAR1-induced RNA editing in patients with COVID-19 could further propagate the inflammatory response by increasing stability of proinflammatory transcripts, as we have previously shown in chronic inflammatory diseases such as atherosclerosis and rheumatoid arthritis [78,79]. For example, upregulation of cathepsin S (CTSS), an elastolytic enzyme that promotes the development of inflammatory, non-stable atherosclerotic plaques [80] could in turn destabilize existing plaques leading to acute coronary events or stroke. Cathepsin S is also involved in major histocompatibility complex (MHC)-II dependent antigen presentation [81], thus providing a link between innate and adaptive immune responses. Of interest, cathepsin S expression is increased in a subgroup of lung capillary endothelial cells along with genes involved in MHC class II-mediated antigen presentation [82], which could participate in initial recognition of SARS-CoV-2 and mounting of systemic inflammatory reaction [83]. Of note, CTSS is only one among thousands of mRNAs, as well as ncRNAs, including miRNAs and IncRNAs that can be affected by RNA editing [78,80,81], offering an additional level of gene regulation during the systematic inflammatory response induced by SARS-CoV-2 infection (Fig. 2).

### 3.1. Brain-heart crosstalk

It is projected that 0.04 % of the overall COVID-19 patients have been affected with neurological diseases (e.g. ischemic strokes, encephalopathy, psychosis) at the central nervous system (CNS) [84]. On another hand, it is estimated that 20 % to 30 % of hospitalized patients develop cardiac injury [85,86]. Clinical data indicate that both the susceptibility to and the outcomes of COVID-19 are strongly associated with cardiovascular disease (reviewed in refs [86,87]). Currently, it is relatively unknown what is the level of communication between the brain and the heart in the context of COVID-19 and which cellular or molecular mechanisms play major roles in this communication [88].

Inflammation may be a potential link between heart and brain communication in the context of COVID-19. It is well accepted that the proteome signature is affected significantly in the acute-phase response in severe COVID-19 patients [89,90]. Results obtained in different studies indicate the up-regulation of IL-6 signalling pathway [89,91,92], which is more affected than other inflammatory pathways such as the tumor necrosis factor and interferon gamma pathways. Both the classical complement pathway and the complement modulators are also activated, C-reactive protein and serum amyloid proteins are up-regulated, and modulators of inflammation such as gelsolin that is part of the extracellular actin scavenger system which removes toxic F-actin filaments are dysregulated [89].

A second important route of communication between heart and brain are the extracellular vesicles (EVs). EVs are lipid vesicles secreted by cells containing several biomolecules (miRNAs, mRNA, proteins) [93] which are involved in inter-organ communication [94]. These EVs can be classified in three different categories according to their biogenesis: (i) exosomes, (ii) microvesicles and (iii) apoptotic bodies. EVs secreted by the brain or the heart have the potential to carry biological information in the brain-heart axis. For example, EVs released by the CNS activate the acute-phase response leading to the hepatic release of acute-phase proteins.
endothelial cells or perivascular cells. Further studies are required to investigate in more detail the role of EVs in the brain-heart axis.

Stem/progenitor cells are also a route of communication between heart and brain. Circulating levels of endothelial progenitor cells (CD45+ CD31− CD34+ CD146−) have been reported to be increased in COVID-19 patients with mild and severe symptoms compared to healthy controls [98]. Interestingly, some endothelial progenitor cells had the phenotype CD34+ KDR− CD19+, indicative of their lymphocyte lineage [99].

3.2. Diagnostic potential of ncRNAs in COVID-19

The major hallmarks of severe COVID-19 are respiratory (pulmonary embolism), cardiac (ischemia, tachyarrhythmia, myocarditis and pericarditis), and neurological (transient ischemic attack and stroke). Up to date, sensitive and reliable markers for the early risk stratification of cardio-neurological complications and mortality risk assessment in COVID-19 patients have not been established yet. Over the past decade, (epi)transcriptome network has emerged as an important player in regulation of virtually all cellular processes and indicators of outcomes of a plethora of disease states including cardiovascular, neurodegenerative disease, cancers and infectious diseases. Clinical applications of RNAs in different human pathologies are on the horizon. Identification of differentially expressed ncRNAs as well as changes in RNA modification profiles and their functional annotation in biofluids of COVID-19 patients may open up new avenues for developing biomarkers against this deadly disease. For instance, several properties of ncRNAs particularly miRNAs suggest their potential value as biomarkers for COVID-19 outcome prognosis. They are present and stable in the circulation, they demonstrate tissue-specificity, participate in disease evolution, they are measurable using reliable and sensitive techniques and they are easily accessible from biofluids (“liquid biopsies”). In addition to high sensitivity and specificity, RNA analysis is cheaper compared to protein analysis and offers a greater overview of cell regulation and states compared to DNA analysis.

3.3. Future of COVID-19 diagnostics and therapy

The scientific community around the globe is working frenetically to support emergency responses to the ongoing pandemic by implementing innovative research strategies aiming to develop diagnostic, prognostic and therapeutic solutions for COVID-19, as well as to prepare for future similar issues. The battle against COVID-19 and preparedness for future pandemics rely on the development of innovative approaches to identify risk stratification biomarkers and therapeutic targets capable to predict disease evolution and improve clinical outcomes. Although several types of vaccines are currently administered against COVID-19, it is too early to predict how efficient they will be to eliminate SARS-CoV-2, notably due to the capacity of the virus to mutate and generate novel and potentially more dangerous variants. Taking into account high transmissibility of new viral variants and heterogeneity of clinical symptoms among COVID-19 patients, there is a critical need to foster multi-omics approaches to discover novel diagnostics and therapeutic solutions for COVID-19.

Recent intensified interest in (epi)transcriptomic research by scientific community worldwide, pharmaceutical industries and biotechnology companies and the lessons learned from COVID-19 pandemic should be applied for the future benefit of patients and the healthcare system.

A comprehensive understanding of the complex and multilayer interaction between SARS-CoV-2 and host immune responses in COVID-19 patients is fundamental to defining the effectiveness of treatments, predicting disease evolution, and for understanding heterogeneity of disease severities and outcomes [100]. Two recently published studies demonstrate the power of multi-omics approach to characterize a sharp disease-state shift between mild and moderate illness [101,102]. A wider application of multi-omics high-throughput technologies may contribute to refine our knowledge of SARS-CoV-2 pathogenicity and decipher fundamental changes at genomic, transcriptomic, proteomics and metabolomics levels. In this review paper, we gathered recently published studies investigating transcriptomic fluctuations upon SARS-CoV-2 infection, with a focus on the brain-heart axis since neurological and cardiovascular events and sequelae are of utmost prevalence and importance. Identification of dysregulated ncRNAs and epitranscriptomics changes during SARS-CoV-2 infection may constitute a source of biomarkers for early identification of patients at risk of cardiovascular and neurological events. Additionally, a deep mining of the interplay between (epi)transcriptome affecting both the brain and the heart and interacting with SARS-CoV-2 may provide significant mechanistic insights and catalyse the discovery of novel drugs to limit adverse events, thereby impacting on healthcare and improving patients’ outcomes.

3.4. Extracellular vesicles based COVID-19 therapeutics

Several EVs based therapies for the treatment of COVID-19 are under clinical evaluation due to their immunomodulatory properties. According to ClinicalTrials.gov there are four clinical trials (phase I) and one pilot clinical study (NCT04276987) running or completed for the therapeutic evaluation of EVs. The EVs originated either from mesenchymal stem cells (MSC) (NCT04602244; NCT04491240; NCT04276987), T cells (NCT04389385) or bone marrow cells (NCT04493242). One of the completed randomized trials (NCT04491240; total number of COVID-19 patients untreated and treated with EVs were 10 and 20, respectively) reported no adverse reactions of MSC derived-EVs administered in patients by inhalation. These clinical trials are justified by the encouraging results obtained by the use of EVs in pre-clinical lung injured models such as acute respiratory distress syndrome, lipopolysaccharide-induced lung injury and pneumonia (reviewed in reference [103]).

4. Concluding remarks and future perspectives

Although the rate of hospitalization of SARS-CoV-2 infected individuals is diminishing, the COVID-19 pandemic remains a significant public health threat worldwide, mostly due to emerging long-term sequelae (“long COVID”). An in-depth characterization of the omics contributors of the disease would allow refining diagnostic strategies, identify markers of disease severity and progression, and finally identify novel therapeutic approaches.

Rapidly evolving high-throughput technologies are well positioned to allow discoveries that will increase our understanding of SARS-CoV-2 interaction with host immune response. This may lead to new biomarkers and treatments that can, if possible at the same time, identify and treat patients at risk of developing severe forms of COVID-19 or long-term sequelae affecting for instance the cardiovascular of neurological systems. For complex traits such as COVID-19 involving multiple biological pathways and organs, omics approaches may allow the identification of novel disease mechanisms to further understand and better characterize SARS-CoV-2 pathophysiology. In line with that, dynamic monitoring of cardiovascular and neurological symptoms and organ dysfunction with laboratory markers might help unravel the underlying pathways linking cardiovascular and neurological disorders to poor clinical outcome.

Integrative (epi)transcriptomic approaches have the potential to aid personalizing healthcare for optimal outcomes. This holds true not only for COVID-19 but also for any other disease with an (epi)transcriptomic component. After the demonstration of their — until recently doubtable — usefulness as vaccines, RNAs are now entering a new era of RNAs for biomarkers and therapeutic purposes. Hence, more examples of the use of RNAs in precision medicine are expected in the few upcoming years.
Funding

AJ is funded by the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement 893435.

YD is funded by the EU Horizon 2020 project COVIRNA (Grant Agreement # 101016072), the National Research Fund (grants # C14/BM, 8225223, C17/BM/11613033 and COVID-19-2020-1/14719777/miCOVID), the Ministry of Higher Education and Research, and the Heart Foundation–Daniel Wagner of Luxembourg.

KS is supported by grants from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (MODVASC, grant agreement No 759248) and the German Research Foundation DFG (SFB834 B12, project number 75732319).

LF is funded by the European Union’s Horizon 2020 research and innovation programme under grant agreement numbers 764958 (project NANOSTEM), 952266 (project RESETTagging) and 101016072 (project COVIRNA), INTERREG fund (Projects “NeuroAtlantic” and 2IQBioneuro, Ref: EAPA_791/2018 and Ref: 0624_2IQBIONEURO_6, respectively) and Portuguese Research Funds (project POCI-01-0145-FEDER-029229).

A.H.B is supported by the BHF Chair of Translational Cardiovascular Sciences (CH/11/2/2873), BHF programme grants (RG/14/3/30706, RG/20/5/34796 and RG/19/3/34265), BHF Centre for Vascular Regeneration and BHF Research Excellence Award RE/18/5/34216. He is also funded by the EU Horizon 2020 project COVIRNA (# 101016072).

Author contributions

All authors contributed substantially to all aspects of the article.

Declaration of competing interest

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:

Yvan Devaux reports was provided by Luxembourg Institute of Health. Yvan Devaux holds patents related to diagnostic and therapeutic applications of RNAs.

Acknowledgements

This article is based upon work from EU-CardioRNA COST Action CA17129 (www.cardiorna.eu) supported by (European Cooperation in Science and Technology).

References

[1] Gao YM, Xu G, Wang B, Liu BC. Cytokine storm syndrome in coronavirus disease 2019: a narrative review. J Intern Med. 2021;289(2):147-61.
[2] Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, U.K. HHS across speciality collaboration, COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033-4.
[3] Ragab D, Salah Eldin H, Taeimah M, Khatib R, Salem R. The COVID-19 cytokine storm: what we know so far. Front Immunol. 2020;11:1446.
[4] Lazaridis C, Vlahogiannis NI, Bajkacianis C, Spyridopoulos I, Stamatelopoulos K, Barbarisi G, Massi S, Vlahogiannis NI, Sopova K, Mengozzi A, Ghiadoni L, van der Most P, Moccia P, Waliany S, Castaldi C, Heijne J, Ng E, Wheeler J, Alfajaro MM, Levavasseur E, Fontes B, Ravindra NG, Van Dijk D, Mane S, Gunel M, Ring A, Kazmi SAJ, Zhang K, Wilen CB, Horvath TL, Plu I, Haik S, Thomas JL, Louvi A, Farbadshan SF, Huttner A, Seilhen D, Ronier N, Bilgic K, Iwasaki A. Neuroinflammation in SARS-CoV-2 and human brain. J Exp Med. 2021;218(3):60.
[5] Goodrich JA, Jugel JF. Non-coding-RNA regulators of RNA polymerase II transcription. Nat Rev Mol Cell Biol. 2006;7(8):612–6.
[6] Radimov L, Robinson EL, Juric A, Carpuscu I, deWitt LD, Emanuelli C, Fradini P, Wu G, Gyoseynian M, Hackl M, Karadoukas-Hadzic R, Lastrifis K, Martelli F, Nham E, Potoconjak I, Satagopam V, Schneider R, Thum T, Devaux Y. Cardiovascular RNA markers and artificial intelligence may improve COVID-19 outcome: a position paper from the EU-CardioRNA COST action CA17129. Cardiovasc Res. 2021;117(1):1823–40.
[7] Zheng HY, Xu M, Yang CX, Tian RH, Zhang M, Li JJ, Wang XG, Ding ZL, Li GM, Xi L, He YG, Dong QX, Yao YG, Zheng YT. Longitudinal transcriptome analyses show robust T cell immunity during recovery from COVID-19. Signal Transduct Target Ther. 2020;5(1):294.
[8] Mone P, Gambardella J, Wang X, Jankauskas SS, Matarese A, Santulli G. miR-24 targets the transmembrane glycoprotein neuropilin-1 in human brain microvascular endothelial cells. Noncoding RNA. 2021;7(1):9.
[9] Tang H, Gao Y, Li Z, Miao Y, Huang Z, Liu X, Xie L, Li H, Wen W, Zheng Y, Su W. The noncoding and coding transcriptional landscape of the peripheral immune response in patients with COVID-19. Clin Transl Med. 2020;10(6):e200.
[10] Garg A, Seeliger B, Derda AA, Xiao K, Gietz A, Sennonenko K, Pink I, Hoepfner MM, Weile T, Bauersachs J, David S, Bar C, Thum T. Circulating cardiovascular microRNAs in critically ill COVID-19 patients. Eur J Heart Fail. 2021;23(3):468–75.
[11] Lu D, Chatterjee S, Xiao K, Riedel I, Wang Y, Foo R, Bar C, Thum T. MicroRNAs targeting the SARS-CoV-2 entry receptor exporter in cardiomyocytes. J Mol Cell Cardiol. 2020;148:46–69.
[12] Gutmann C, Khamina K, Theofilatos K, Diem dorfer AR, Barmas SA, Nabaeabucks A, Fish M, McPhail MW, O’Gallagher K, Schmidt LE, Ossel C, Auzierger G, Napoli S, Mejaf SB, Trovato F, Sauderan D, Berrett B, Roy R, Edgeworth JD, Shah AM, Hayward AC, Trayb M, Hackl M, Eichinger S, Shankar-Hari M, Mayr M. Association of cardiotubeloma microRNAs with COVID-19 severity and mortality. Cardiovasc Res. 2021;112(8):161–74.
[13] Li C, Hu C, Li L, Li JH. Differential microRNA expression in the peripheral blood from human patients with COVID-19. J Clin Lab Anal. 2020;34(10):e23590.
[14] Beck BE, Wood CD, Whensham GR, Triaryl phosphate poisoning in cattle. Vet Pathol. 1977;14(2):128–37.
[15] Farr RJ, Rootes CL, Rowntree LC, Nguyen THO, Hensen L, Kedzierski L, Cheng AC, Ferracin M, Cippolina C, Benes PV, Tamminen M, Coronel C. miR-1207-5p can contribute to dysregulation of inflammatory response in COVID-19 via targeting SARS-CoV-2 RNA. Front Cell Infect Microbiol. 2020;10:586592.
[16] Santinilli J, Giuliani A, Machialetto G, Lapiorteria N, Popomorpi C, Ferrarini A, Svegliati Baroni S, Pavani M, Morretti G, Gabrielli A, Procopio AD, Ferrarini M, Bonafe M, Olivieri F. Decreased serum levels of the inflamming marker mir-146a are associated with clinical non-response to tocilizumab in COVID-19 patients. Med Ageing Dev. 2021;19(11):114131.
[17] Canton A, Fonseca AS, Ferreira A, Azevedo MLV, Vaz de Paula CB, Nagashima S, Machado-Sousa C, Miggliola A, Baena CP, de Noronha L, Cavalli LR. Deregulated microRNA expression is associated with endothelial dysfunction in post-mortem lung biopsy of COVID-19 patients. Am J Physiol Lung Cell Mol Physiol. 2020;320(3):L405–12.
[18] Daly JL, Simontelli B, Klein K, Chen KE, Williamson MK, Anton-Flagaro C, Sherkman DK, Simon-Gracia L, Bauer M, Hollandi R, Greber UF, Horvath P, Sessions RB, Helenius A, Hiscox JA, Teesalu T, Matthews DA, Davidson AD, Collins BM, Cullen R. Identification of the transmembrane glycoprotein neuropilin-1 in human brain microvascular endothelial cells. J Neurosci. 2020;40(26):5865–76.
[19] D’Souza SS, Etchegaray JP, Bolling K, Wang X, Weir P, van der Most P, van der Most P, Wang X, Weir P, van der Most P, Mocciola P, Waliany S, Castaldi C, Heijne J, Ng E, Wheeler J, Alfajaro MM, Levavasseur E, Fontes B, Ravindra NG, Van Dijk D, Mane S, Gunel M, Ring A, Kazmi SAJ, Zhang K, Wilen CB, Horvath TL, Plu I, Haik S, Thomas JL, Louvi A, Farbadshan SF, Huttner A, Seilhen D, Ronier N, Biliuv K, Iwasaki A. Neuroinflammation in SARS-CoV-2 and human brain. J Exp Med. 2021;218(3):60.
[31] Meydan C, Mader N, Soroll H. The near death of COVID-19: NEAT1, DANGR, and Co-DX, a cholesterol-driven link to inflammation in the proximal immune system. 2020;11:590060.

[32] Saxhaug AL, Almeh AM. Identification of PBMCD-based molecular signature associated with COVID-19 disease severity. Heliosis. 2021;7(5):e6866.

[33] Saxhaug H, Vishingabalu R, Elkord E, Almeh AM. Single-cell transcriptomics analysis highlight important role of the stimulatory and inhibitory macrophages in the pathogenesis of severe COVID-19. Cells. 2020;9(11).

[34] Vlachogiannis G, Sachse M, Georgiopoulos G, Zoropas E, Bampountas D, Delilis D, Bonini F, Galysys G, Sigala S, Tzamopoulou K, Gatsiou A, Steklos K. Adenosine-to-ino sine RNA editing controls the stability of the proximal long non-coding RNA NEAT1 in atherosclerotic cardiovascular disease. J Mol Cardiol. 2021;160:111–20.

[35] Cheng J, Zhou X, Feng W, Jia M, Zhang X, Xu T, Luan M, Pan Y, Zhang S, Zhou Z, Wen S, Liao F, Zhou C. RNA-seq profiling by digital PCR analysis profiling in COVID-19 patients. J Mol Med. 2021;25(10):4753–64.

[36] Zhang Y, Li B, Bai Q, Wang P, Wei G, Li Z, Hu L, Tian Q, Zhou J, Huang Q, Wang Z, Yue S, Wu J, Yang L, Zhou X, Jiang Ni, Ni T, Ye L, Wu Y. The Wnt-Signaling RNA editing system is involved in the regulation of the dual effects of IL-7 signaling. Signal Transduct Target Ther. 2021;6(1):126.

[37] Gatsiou A, Steklos K. Dawn of epitranscriptomic medicine. Circ Genom Precis Med. 2019;12(4):260–1.

[38] Feng L, Chen R, Shi Z, Li Y, Sheng C, Yang C, Chen L, Sun J. Tanshinone IIA inhibits apoptosis in the myocardium by inducing microRNA-152-3p expression and thereby downregulating PTEN. Am J Transl Res. 2016;8(7):3124–30.

[39] Zhao Y, Zhao Z, Wang Y, Zhou Y, Ma Y, Zuo W. Single-cell RNA expression profiling in the acute and late phase of critically ill COVID-19 patients. Clin Nutr ESPEN. 2021;43:100050.

[40] Whitle J, Molleringer J, MacLeod D, Haines K, Wischmeyer PE, L-C-S. Group. Persistent hypermetabolism and longitudinal energy expenditure in critically ill patients with COVID-19. Crit Care. 2020;24(1):581.

[41] Zacker BH. Novel mechanisms and sympathetic regulation in chronic heart failure. Hypertension. 2006;48(6):1005–11.

[42] Vlachogiannis G, Verru KM, Stellos K, Sifakis PP, Paraskevis D. The role of A-to-I RNA editing in infection by RNA viruses: possible implications for SARS-CoV-2 infection. Clin Immunol. 2020;216:104725.

[43] Lerner T, Papavassiliou FN, Pecori R. RNA Editors. Coauthors, and mRNA targets: an overview of the C-to-U RNA editing machinery and its implication in human disease. Genes (Basel). 2018;9(1).

[44] Zhao Y, Yang X, Wang Y, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL, Chen HD, Chen J, Luo Y, Guo H, Jiang RD, Liu MQ, Chen YN, Wang XR, Yang Z, Zheng XS, Zhao K, Chen CJ, Deng F, Liu LY, Yan B, Zhan FX, Yang WW, Xiao GF, Shi ZL. A pneumonia outbreak associated with a novel coronavirus of probable bat origin. Nat Med. 2020;27(2):277–84.

[45] Wang R, Hroumou Y, Zheng YH, Yin C, Wei GW. Host immune response driving SARS-CoV-2 evolution. Viruses. 2020;12(10).

[46] Di Giorgio S, Martignago F, Furtica MG, Mattiuz G, Conticello SG. Evidence for host-dependent RNA editing in the transcriptome of SARS-CoV-2. Sci Adv. 2020;6(25):eabb813.

[47] Samuel CE. Adenosine deaminases acting on RNA (ADARs) are both antiviral and pro-viral. Virology. 2011;411(2):384–96.

[48] Hou YJ, Chiba S, Halfmann P, Ehre C, Kuroda I, Dimond 3rd K, Leit SL, Schafer A, Nakajima N, Takahashi K, Lee RE, Masenik TM, Graham R, Edwards CE, Tse LV, Okuda K, Markmann AJ, Bartlett D, de Silva A, Margolis D, Boucher RC, Randell SH, Phillips JA, Grollmans LE, Yawoou B, Yuzis RS. SARS-CoV-2 D614G variant exhibits efficient replication capacity ev. Nature. 2020;579(7798):244–8.

[49] Ozo Z, Zhao Y, Ode S, Kan T, Tusa I, Imi K, Miyoshi K, Kishigami S, Ueno T, Iwamoto Y, Suzuki T, Takizawa K. Analysis of the ACE2-dependent SARS-CoV-2 infection rate in mice with enhanced ACE2 binding affinity. Nat Commun. 2021;12(1):848.

[50] Scadden AD. The RSC unit subunit TkdN binds to hyper-edited double-stranded RNA and promotes its clearance. Nat Struct Mol Biol. 2005;12(6):489–96.

[51] Harris RS, Dudley JP. APOBEC and virus restriction. Virology. 2015;479–480:131–5.

[52] Picardi E, Mano L, Pessole G. Detection of A-to-I RNA editing in SARS-CoV-2. Genes (Basel). 2021;13(1).

[53] Libby P, Lanfer T. COVID-19 is, in the end, an endothelial disease. Eur Heart J. 2020;41(6):695–706.

[54] Varga Z, Flammer AJ, Steiger P, Haberecker M, Zinkernagel AS, Mehra MR, Schaper BA, Rau N, Chrobak M, Schaffitzel C, Mohn T. Increased adenosine-to-inosine RNA editing in rheumatoid arthritis. Arthritis Res Ther. 2020;22(1):32.

[55] Romanso M, Siromi M, Toniatti C, Polentarutti N, Frascella F, Ghezzi P, Faggioni R, Luini W, Van Hinderghem V, Sozanni S, Bussolino F, Poli V, Ciliberto G, Mantovani A. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment during COVID-19. Int J Mol Sci. 2021;22(4):1835.

[56] Spadaro S, Fogaggio A, Campo G, Zucchetti O, Verri M, Ottaviani I, Tunstall T, Grasso S, Scaramuzzo M, Vurfa C, Vezzi P, Faggioni R, Papi G. Dysregulated RNA editing controls cathepsin S expression in atherosclerosis by enabling HuR-mediated mRNA stability. J Biol Chem. 2020;296(13):102329.

[57] Shi GP, Villadangos JA, Dranoff G, Small C, Gu L, Haley KJ, Riese R, Ploegh HL, Tanaka Y, Matsunaga S, Wu J, Yang L, Zhou X, Jiang L, Ni T, Ye L, Wu Y. The lncRNA Snhg1-Vps13D vesicle trafficking system promotes autophagy and enhances the antiviral response in macrophages. Front Immunol. 2020;11:3290.

[58] Libby P, Lanfer T. COVID-19 is, in the end, an endothelial disease. Eur Heart J. 2020;41(6):695–706.

[59] Varga Z, Flammer AJ, Steiger P, Haberecker M, Zinkernagel AS, Mehra MR, Schaper BA, Rau N, Chrobak M, Schaffitzel C, Mohn T. Increased adenosine-to-inosine RNA editing in rheumatoid arthritis. Arthritis Res Ther. 2020;22(1):32.
Ponosova D, De Smet F, Staaf FJT, McLaughlin RJ, Impens F, Lagani V, Vinckier S, Mazzone M, Schoonjans L, Dewerchin M, Eelen G, Karakach TK, Yang H, Wang J, Bolund L, Lin L, Thienpont B, Li LX, Labenbrots D, Luo Y, Carmeliet P. An integrated gene expression landscape profiling approach to identify lung tumor endothelial cell heterogeneity and angiogenic candidates. Cancer Cell. 2020;37(3):421.

Tessen LA, Geldhof V, Panat A, Carmeliet P. Author correction: COVID-19: the vasculature unleashed. Nat Rev Immunol. 2020;20(7):448.

Ellod MA, Benjamin I, Singh B, Lant S, Michael BD, Easton A, Kneen R, Defres S, Sevja J, Solomon T. Neurological associations of COVID-19. Lancet Neurol. 2020;19(7):767–83.

Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, Wang H, Wan J, Wang X, Lu Z. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5(7):811–8.

Akhemrov A, Marban E. COVID-19 and the heart. Circ Res. 2020;126(10):1443–55.

Nishiga M, Wang DW, Han Y, Lewis DB, Wu JC. COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. Nat Rev Cardiol. 2020;17(9):543–58.

Bels D, Zerr I, Martelli F, Doehner W, Devaux Y. RNAs in brain and heart diseases. Int J Mol Sci. 2020;21(10).

Mesner CB, Demichev V, Wendisch D, Michalik L, White M, Freiwald A, Textoris-Taube K, Vernardis SI, Egger AS, Kressel M, Ludwig D, Killian C, Agostini F, Zeleniak A, Thibeault C, Pfeiffer M, Hippenstiel S, Hocke A, von Kalle C, Campbell A, Hayward C, Porteous DJ, Marioni RE, Langenberg C, Lilley KS, Kuebler WM, Mulleder M, Drost C, Suttorp N, Wittenbach M, Kurth F, Sander LE, Raiser M. Ultra-high-throughput clinical proteomics reveals classifiers of COVID-19 infection. Cell Syst. 2020;11(1):11–24.e6.

Shen B, Yi X, Wu X, Zhang L, He T, Wang H, Han W, Wan J, Wang X, Lu Z. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5(7):811–8.

Nishiga M, Wang DW, Han Y, Lewis DB, Wu JC. COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. Nat Rev Cardiol. 2020;17(9):543–58.

Bels D, Zerr I, Martelli F, Doehner W, Devaux Y. RNAs in brain and heart diseases. Int J Mol Sci. 2020;21(10).

Mesner CB, Demichev V, Wendisch D, Michalik L, White M, Freiwald A, Textoris-Taube K, Vernardis SI, Egger AS, Kressel M, Ludwig D, Killian C, Agostini F, Zeleniak A, Thibeault C, Pfeiffer M, Hippenstiel S, Hocke A, von Kalle C, Campbell A, Hayward C, Porteous DJ, Marioni RE, Langenberg C, Lilley KS, Kuebler WM, Mulleder M, Drost C, Suttrop N, Wittenbach M, Kurth F, Sander LE, Raiser M. Ultra-high-throughput clinical proteomics reveals classifiers of COVID-19 infection. Cell Syst. 2020;11(1):11–24.e6.

Shen B, Yi X, Wu X, Zhang L, He T, Wang H, Han W, Wan J, Wang X, Lu Z. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5(7):811–8.

Nishiga M, Wang DW, Han Y, Lewis DB, Wu JC. COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. Nat Rev Cardiol. 2020;17(9):543–58.

Bels D, Zerr I, Martelli F, Doehner W, Devaux Y. RNAs in brain and heart diseases. Int J Mol Sci. 2020;21(10).

Mesner CB, Demichev V, Wendisch D, Michalik L, White M, Freiwald A, Textoris-Taube K, Vernardis SI, Egger AS, Kressel M, Ludwig D, Killian C, Agostini F, Zeleniak A, Thibeault C, Pfeiffer M, Hippenstiel S, Hocke A, von Kalle C, Campbell A, Hayward C, Porteous DJ, Marioni RE, Langenberg C, Lilley KS, Kuebler WM, Mulleder M, Drost C, Suttrop N, Wittenbach M, Kurth F, Sander LE, Raiser M. Ultra-high-throughput clinical proteomics reveals classifiers of COVID-19 infection. Cell Syst. 2020;11(1):11–24.e6.

Shen B, Yi X, Wu X, Zhang L, He T, Wang H, Han W, Wan J, Wang X, Lu Z. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5(7):811–8.